Roche’s Avastin and Novartis AG’s Lucentis Equal for Treating Wet AMD – National Institutes of Health (NIH) Study

Basel, Switzerland, May 01, 2012 (Thomson Reuters ONE via COMTEX) -- Novartis International AG / Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizum…
Read the full story: BioSpace.com Featured News